LOS ANGELES, March 3 (Reuters) - Shares of Amylin Pharmaceuticals Inc fell 5 percent on Monday after U.S. regulators suggested changes to diabetes studies that some analysts said could delay approval of a long-acting version of the company’s diabetes drug.
